Matrix metalloproteinase-9 expression in carotid atherosclerotic plaque and contrast-enhanced MRI in a swine model-Reference-Cited by-同舟云学术

Matrix metalloproteinase-9 expression in carotid atherosclerotic plaque and contrast-enhanced MRI in a swine model

Published:2012-12-07 Issue:1 Volume:6 Page:24-28
ISSN:1759-8478
Container-title:Journal of NeuroInterventional Surgery
language:en
Short-container-title:J NeuroIntervent Surg

Author:

Jiang Xiao-Bing,Yuan Wei-Si,Wang Jin-Shan,Liu Zhong,Liu Dong-Hong,Shi Zhong-Song

Publisher

BMJ

Subject

Neurology (clinical),General Medicine,Surgery

Reference22 articles.

1. Heart disease and stroke statistics—2010 update: a report from the American Heart Association;Lloyd-Jones;Circulation,2010

2. Swine model of carotid artery atherosclerosis: experimental induction by surgical partial ligation and dietary hypercholesterolemia;Ishii;AJNR Am J Neuroradiol,2006

3. Vulnerable plaque in a Swine model of carotid atherosclerosis;Shi;AJNR Am J Neuroradiol,2009

4. Overexpression of matrix metalloproteinase-9 is correlated with carotid intraplaque hemorrhage in a swine model;Jiang;J Neurointerv Surg,2013

5. Neovascularization in human atherosclerosis;Moreno;Circulation,2006

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation of LP-PLA2 and MMP-9 with the occurrence of early neurological deterioration in patients with acute ischemic stroke;Medicine;2024-05-24

2. Development of a fluorescence immunochromatography method for quantitative measurement of matrix metalloproteinase-9;Practical Laboratory Medicine;2024-01

3. Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies;Frontiers in Pharmacology;2023-02-14

4. Immunohistochemical analysis of MMP-9 and COX-2 expression in carotid atherosclerotic plaques among patients undergoing carotid endarterectomy: A prospective study;Journal of Stroke and Cerebrovascular Diseases;2022-11

5. Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS);Vascular Pharmacology;2022-10